Key Takeaways
- Todd James appointed as Executive Vice President and Chief Financial Officer at Bambusa Therapeutics.
- James brings over 20 years of biopharmaceutical industry experience, enhancing the company’s financial leadership and strategy.
- Bambusa is advancing its bispecific antibody pipeline targeting immunology and inflammation with a focus on long-term value creation.
Company Appointment Announcement
Bambusa Therapeutics, a clinical-stage biotechnology firm specializing in next-generation bispecific antibodies for immunology and inflammation (I&I), has announced the appointment of Todd James as its new Executive Vice President and Chief Financial Officer (CFO). This strategic addition aims to bolster the company’s financial leadership as it progresses through its clinical pipeline and executes its growth ambitions.
Dr. Shanshan Xu, the founder and CEO of Bambusa Therapeutics, expressed enthusiasm about James’s appointment, sharing insights from their past interactions. She noted his strong track record in capital markets and strategic leadership, essential attributes as Bambusa works on its innovative bispecific antibody pipeline. The goal is to advance candidates BBT001 and BBT002 into pivotal studies while progressing BBT003 and BBT004 toward proof-of-concept studies by 2028.
James brings over two decades of senior leadership experience within the biopharmaceutical sector, noted particularly for his skills in capital markets, investor relations, and corporate strategy. His most recent position was Senior Vice President of Corporate Affairs and Investor Relations for Acceleron Pharma, which was acquired by Merck for $11.5 billion. During his tenure at Acceleron (2015-2021), he established the investor relations and corporate affairs functions and played a significant role in raising over $1 billion through four successful financing rounds. He has previously been recognized as a top investor relations professional in biotechnology by Institutional Investor magazine.
Before his role at Acceleron, James spent nine years at Trout Group and Trout Capital, advising biopharma firms on investor relations and capital raising. He began his career at Thomson Financial within the Biotechnology Capital Markets Intelligence team and holds a Bachelor of Arts degree in Economics, specializing in Finance from Moravian University.
In his new role, James stated he is eager to collaborate with the Bambusa team to strengthen the company’s financial strategy and external engagement, aiming for transformative outcomes in I&I disease areas while adding long-term value for both patients and investors.
Bambusa Therapeutics is dedicated to developing a portfolio aimed at transforming treatment across various chronic diseases, leveraging its innovative antibody engineering platform. Among its candidates, BBT001 is in Phase Ib development for atopic dermatitis, while BBT002 targets various type 2 inflammatory disorders. Preclinical programs BBT003 and BBT004 focus on gastroenterology and rheumatology, respectively.
The content above is a summary. For more details, see the source article.